Format

Send to

Choose Destination
JACC Basic Transl Sci. 2019 Oct 28;4(6):736-751. doi: 10.1016/j.jacbts.2019.06.002. eCollection 2019 Oct.

A Molecularly Detailed NaV1.5 Model Reveals a New Class I Antiarrhythmic Target.

Author information

1
Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri.
2
Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri.

Abstract

Antiarrhythmic treatment strategies remain suboptimal due to our inability to predict how drug interactions with ion channels will affect the ability of the tissues to initiate and sustain an arrhythmia. We built a multiscale molecular model of the Na+ channel domain III (domain III voltage-sensing domain) to highlight the molecular underpinnings responsible for mexiletine drug efficacy. This model predicts that a hyperpolarizing shift in the domain III voltage-sensing domain is critical for drug efficacy and may be leveraged to design more potent Class I molecules. The model was therefore used to design, in silico, a theoretical mexiletine booster that can dramatically rescue a mutant resistant to the potent antiarrhythmic effects of mexiletine. Our framework provides a strategy for in silico design of precision-targeted therapeutic agents that simultaneously assesses antiarrhythmic markers of success and failure at multiple spatial and time scales. This approach provides a roadmap for the design of novel molecular-based therapy to treat myriad arrhythmia syndromes, including ventricular tachycardia, heart failure arrhythmias, and inherited arrhythmia syndromes.

KEYWORDS:

APD, action potential duration; BCL2000, basic cycle length of 2,000 ms; DIII-VSD, domain III voltage-sensing domain; EAD, early afterdepolarization; IC50, half-maximal inhibitory voltage; LQT3, long QT syndrome type 3; RFI, recovery from inactivation; SSA, steady-state availability; UDB, use-dependent block; V1/2, half-maximal voltage; VSD, voltage-sensing domain; arrhythmias; computational biology; ion channels; pharmacology; translational studies

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center